指南与共识慢阻肺

日本呼吸学会慢性阻塞性肺疾病管理指南第7版(2026)

The JRS guideline for the management of chronic obstructive pulmonary disease 7th edition 2026
RSS 订阅 · 指南共识 · 慢阻肺 · 2026-07-14

日本呼吸学会于2026年3月发布第7版慢阻肺管理指南,距第6版约四年。指南聚焦稳定期与急性加重期管理目标,正式采用GOLD 2023病因分型,将CT检出的黏液栓识别为独立预后因素,并把细胞衰老纳入疾病机制。指南保留15个临床问题并新增7个(CQ16-22),覆盖长期大环内酯类抗生素、支气管镜下肺减容及急性加重综合管理,新增度普利尤单抗用于2型炎症且频繁急性加重患者,证据分级采用Minds/GRADE框架。

要点

  • 正式采用GOLD 2023病因分型,新增细胞衰老为疾病机制
  • CT检出的黏液栓被认定为独立预后因素
  • 新增度普利尤单抗推荐用于2型炎症且频繁急性加重者

核心结论

  • 第7版JRS指南在稳定期与急性加重期管理上纳入病因分型、黏液栓预后价值与细胞衰老机制等概念更新。
  • 心血管风险等合并症管理在急性加重期及之后被提升为核心管理目标。

研究设计与样本

  • 日本呼吸学会(JRS)制定并发布第7版慢阻肺管理指南,证据分级采用Minds/GRADE框架。
  • 指南保留上一版15个临床问题(CQ),并新增7个临床问题(CQ16-22)。

主要发现

  • 日本40岁以上成人慢阻肺患病率估计为8.6%,但仅不足10%的患者获得正式诊断。
  • 指南强调日本患者体型偏瘦、急性加重率较低及哮喘-慢阻肺重叠(ACO)高发等特征,作为日本特异性管理策略的驱动因素。
  • 新增CQ覆盖长期大环内酯类抗生素、支气管镜下肺减容及包括支气管扩张剂、全身糖皮质激素、抗生素和呼吸支持在内的急性加重综合管理。

关键数值与推荐

  • 正式采用GOLD 2023病因分型(etiotype classification)。
  • 将CT检出的黏液栓(mucus plugging)认定为独立预后因素。
  • 将细胞衰老(cellular senescence)纳入疾病机制。
  • 新增推荐度普利尤单抗用于2型炎症且频繁急性加重的患者。

临床怎么用

  • 指南面向呼吸专科医师与全科医师,提供贴合日本临床情境的循证推荐。
  • 临床应关注合并症管理,尤其是急性加重期间及之后的心血管风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respir Investig. 2026 Sep;64(5):101482. doi: 10.1016/j.resinv.2026.101482. Epub 2026 Jul 14. ABSTRACT Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality in Japan, with an estimated prevalence of 8.6% among adults over 40 years of age, yet fewer than 10% of affected individuals receive a formal diagnosis. The Japanese Respiratory Society (JRS) published the 7th edition of the JRS Guidelines for the Management of COPD in March 2026, approximately four years after the 6th edition. This article provides a translated summary of the guidelines, focusing on management goals and both stable- and exacerbation-phase management. The 7th edition incorporates several conceptual advances, including formal adoption of the GOLD 2023 etiotype classification, recognition of CT-detected mucus plugging as an independent prognostic factor, and incorporation of cellular senescence as a disease mechanism. Unique characteristics of Japanese patients including lean body composition, lower exacerbation rates and high prevalence of asthma-COPD overlap (ACO) are highlighted as drivers of Japan-specific management strategies. Comorbidity management, particularly cardiovascular risk during and after exacerbations, is elevated to a core management goal. The guidelines retain 15 clinical questions (CQs) from the prior edition and introduces 7 new CQs (CQ16-22), addressing long-term macrolide antibiotics, bronchoscopic lung volume reduction, and comprehensive exacerbation management, including bronchodilators, systemic corticosteroids, antibiotics, and respiratory support. Dupilumab is newly recommended for patients with type 2 inflammation and frequent exacerbations. Evidence grading follows the Minds/GRADE framework. These guidelines provide practical, evidence-based recommendations tailored to the Japanese clinical context, applicable to both respiratory specialists and general practitioners. PMID: 42447589 | DOI: 10.1016/j.resinv.2026.101482

来源:指南共识 · 慢阻肺,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 慢阻肺:The JRS guideline for the management of chronic obstructive pulmonary disease 7th edition 2026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。